Abstract： Objective： To observe the clinical effect of modified Fuyang Huayin Prescription on hepatocellular carcinoma (HCC). Methods： A total of 91 patients with HCC were divided into the control group and the observation group according to the coin tossing method，with 45 and 46 cases in each group respectively. The control group was given transarterial chemoembolization (TACE) for treatment， and the observation group was additionally treated with modified Fuyang Huayin Prescription based on the treatment of the control group. Before and after treatment，the indexes of liver function，including alanine aminotransferase (ALT)， aspartate aminotransferase (AST)， and total bilirubin (TB)， the indexes of angiogenic factors ， including vascular endothelial growth factor (VEGF) and transforming growth factor- β1 (TGF- β1)， the indexes of tumor markers， including alpha fetoprotein (AFP)， alpha fetoproteinheteroplasmon ratio(AFP- L3) and golgin protein 73 (GP73)， and traditional Chinese medicine (TCM) syndrome scores were compared between the two groups. The clinical effects and incidence of adverse reactions in the two groups were also evaluated. Results： After treatment， the total remission rate was 80.43% in the observation group， higher than that of 60.00% in the control group (P＜0.05). After treatment，the levels of GP73，AFP and AFP-L3 ratio in the two groups were decreased when compared with those before treatment (P＜0.05)，and the above three levels in the observation group were lower than those in the control group (P＜0.05). After treatment， the AST， ALT and TB in the two groups were decreased when compared with those before treatment (P＜0.05)，and the indexes of liver function in the observation group were lower than those in the control group (P＜0.05). After treatment，the VEGF，TGF-β1 and TCM syndrome scores in both groups were significantly decreased when compared with those before treatment (P＜0.05)， and the indexes of angiogenic factors and the TCM syndrome scores in the observation group were lower than those in the control group (P＜0.05). There was no significant difference being found in the comparison of incidence of adverse reactions in both groups (P＞0.05). Conclusion： Modified Fuyang Huayin Prescription has a significant curative effect on patients with advanced hepatocellular carcinoma， which can effectively improve the liver function of patients and decrease the levels of angiogenic factors and tumor markers，with better safety.